These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 18680823

  • 1. [Treatment of later phases of Parkinson disease].
    Tison F.
    Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F85-8. PubMed ID: 18680823
    [No Abstract] [Full Text] [Related]

  • 2. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM, Houeto JL.
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [Abstract] [Full Text] [Related]

  • 3. Peripheral edema and dopamine agonists in Parkinson disease.
    Tan EK.
    Arch Neurol; 2007 Oct; 64(10):1546-7; author reply 1547. PubMed ID: 17923645
    [No Abstract] [Full Text] [Related]

  • 4. Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease.
    Pot C, Oppliger R, Castillo V, Coeytaux A, Hauser C, Burkhard PR.
    Neurology; 2005 Jan 25; 64(2):392-3. PubMed ID: 15668455
    [No Abstract] [Full Text] [Related]

  • 5. Peak-dose dyskinesia; an acceptable price for mobility in late-stage Parkinson's disease?
    Wenzelburger R.
    Clin Neurophysiol; 2005 Sep 25; 116(9):1997-8. PubMed ID: 16055380
    [No Abstract] [Full Text] [Related]

  • 6. [Dopamine agonist is effective in Parkinson disease not only against tremor. Depression is also improved].
    MMW Fortschr Med; 2002 May 06; Suppl 2():88. PubMed ID: 12070869
    [No Abstract] [Full Text] [Related]

  • 7. Are there clinically significant differences between dopamine agonists.
    Stocchi F, Vacca L, Onofrj M.
    Adv Neurol; 2003 May 06; 91():259-66. PubMed ID: 12442684
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [New perspectives in the treatment of the motor complications associated with chronic treatment of Parkinson disease].
    Linazasoro G.
    Neurologia; 1999 Oct 06; 14(8):393-406. PubMed ID: 10609463
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The management approaches to dyskinesia vary from country to country.
    Woitalla D, Mueller T, Russ H, Hock K, Haeger DA.
    Neuroepidemiology; 2007 Oct 06; 29(3-4):163-9. PubMed ID: 18043000
    [Abstract] [Full Text] [Related]

  • 13. Agonists versus levodopa in PD: the thrilla of whitha.
    Montgomery EB.
    Neurology; 2003 Nov 25; 61(10):1462; author reply 1462-3. PubMed ID: 14638991
    [No Abstract] [Full Text] [Related]

  • 14. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
    Stacy M, Galbreath A.
    Clin Neuropharmacol; 2008 Nov 25; 31(1):51-6. PubMed ID: 18303491
    [Abstract] [Full Text] [Related]

  • 15. Mechanisms of motor complications in treatment of Parkinson's disease.
    Kumar A, Huang Z, de la Fuente-Fernández R.
    Adv Neurol; 2003 Nov 25; 91():193-201. PubMed ID: 12442678
    [No Abstract] [Full Text] [Related]

  • 16. Use of apomorphine in clinical practice.
    MacMahon DG.
    Adv Neurol; 1999 Nov 25; 80():529-33. PubMed ID: 10410767
    [No Abstract] [Full Text] [Related]

  • 17. [Melanomas and basal cell carcinomas in a patient with Parkinson disease].
    Hiraldo A, Gómez-Moyano E, Martínez S, Sanz A.
    Actas Dermosifiliogr; 2010 Nov 25; 101(1):95-6. PubMed ID: 20109402
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of Parkinson's disease--where do we go from here?
    Suchowersky O.
    Nat Clin Pract Neurol; 2006 Sep 25; 2(9):461. PubMed ID: 16932605
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.